Publication Date:
2018-01-04
Description:
In this issue of Blood, Hill and colleagues characterized infectious complications in patients with relapsed or refractory B-cell malignancies after treatment with CD19-targeted chimeric antigen receptor–modified T (CAR-T) cells in a phase 1/2 study.1 This is the first study that systemically analyzed infectious events in CAR–T-cell–treated patients.
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine